Literature DB >> 27924477

Assessing Anti-miR Pharmacology with miRNA Polysome Shift Assay.

John R Androsavich1.   

Abstract

Target engagement measurements are critical for evaluating developmental drug candidates and their pharmacological activity. microRNA (miRNA) Polysome Shift Assay enables measurement of anti-miR drug target engagement (i.e. extent of miRNA inhibition) without the need to pre-identify or pre-validate downstream miRNA-regulated genes. This makes it useful for assessing anti-miR activity in target tissues or cells where biology of the inhibited miRNAs may not be well understood. In addition, miRNA Polysome Shift Assay can be multiplexed to assess inhibition of multiple miRNAs by a single anti-miR, thus guiding drug optimization for enhancing or avoiding these activities as desired. This chapter outlines the miRNA Polysome Shift Assay technique, describes sample preparation and quality control, and how to calculate and interpret results.

Entities:  

Keywords:  Anti-miR oligonucleotides; Pharmacology; Polysomes; microRNAs; microRNAs/antagonists and inhibitors

Mesh:

Substances:

Year:  2017        PMID: 27924477     DOI: 10.1007/978-1-4939-6563-2_7

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

Review 1.  Improved Nucleic Acid Therapy with Advanced Nanoscale Biotechnology.

Authors:  Yuhua Weng; Qianqian Huang; Chunhui Li; Yongfeng Yang; Xiaoxia Wang; Jie Yu; Yuanyu Huang; Xing-Jie Liang
Journal:  Mol Ther Nucleic Acids       Date:  2019-12-17       Impact factor: 8.886

2.  LncRNA NORAD facilitates oral squamous cell carcinoma progression by sponging miR-577 to enhance TPM4.

Authors:  Change Qi; Jianwei Liu; Pengnv Guo; Yali Xu; Jing Hu; Xiaomei Han
Journal:  Biol Direct       Date:  2022-01-06       Impact factor: 4.540

Review 3.  Gene therapy to enhance angiogenesis in chronic wounds.

Authors:  Elnaz Shaabani; Maryam Sharifiaghdam; Reza Faridi-Majidi; Stefaan C De Smedt; Kevin Braeckmans; Juan C Fraire
Journal:  Mol Ther Nucleic Acids       Date:  2022-08-17       Impact factor: 10.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.